U.S. neuroscientists say they have designed a gene that enhances memory and learning ability in animals under stress.
Stanford University researchers say their experimental technique might lead to new forms of gene therapy that can reduce the severe neurological side effects of steroids, which are prescribed to millions of patients with arthritis, asthma and other illnesses.
Neuroendocrinologist Professor Robert Sapolsky, co-author of the study, and colleagues created a chimera -- an experimental strand of DNA made with two genes stitched together, in this case a glucocorticoid-receptor gene from a rat combined with an estrogen-receptor gene from a human.
When this new chimeric gene was injected into the hippocampus of a rat, the gene produced new protein receptors that quickly converted stress-inducing glucocorticoids into beneficial estrogen signals.
"They suggest this gene therapy not only blocks the deleterious effects of glucocorticoids, but actually enhances spatial memory and learning through estrogen-controlled events, even in the presence of stress," said Sapolsky. "Seeing this enhancement effect was pretty exciting. It's the best we could have hoped for.
The research appears in the current issue of the Journal of Neuroscience.
Copyright 2006 by United Press International
Related stories:
Scientists use gene therapy to improve memory and learning in animals
Stanford University neuroscientists have designed a gene that enhances memory and learning ability in animals under stress. Writing in the Nov. 8 issue of the
Journal of Neuroscience, the Stanford team says that the experimental technique might one day lead to new forms of gene therapy that can reduce the severe neurological side effects of steroids, which are prescribed to millions of patients with arthritis, asthma and other illnesses.
Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
International team reveals first prognosticator of survival in aggressive cancer
The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to an international collaboration of researchers, including scientists at the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University in Philadelphia, PA, the Department of Human Pathology and Oncology, University of Siena and the Center of Oncological Research of Mercogliano (CROM) in Avellino, Italy.
New methods identify and manipulate 'newborn' cells in animal model of Parkinson's disease
When cells in the brain are lost through disease or injury, neighboring cells begin to divide and multiply, but only a few areas in the brain are able to produce new neurons. Patients with Parkinson's disease suffer degeneration of certain neurons that reside in an area of the brain called the substantia nigra and project into the striatum. Many of the newborn cells in these areas have not been well described because of limitations of methods used to characterize them.
Researchers piece together gene 'network' linked to schizophrenia
Reporting this week in the Archives of General Psychiatry, researchers at the Johns Hopkins University School of Medicine have uncovered for the first time molecular circuitry associated with schizophrenia that links three previously known, yet unrelated proteins.
New master switch found in the brain that regulates appetite and reproduction
Body weight and fertility have long known to be related to each other – women who are too thin, for example, can have trouble becoming pregnant. Now, a master switch has been found in the brain of mice that controls both, and researchers at the Salk Institute for Biological Studies say it may work the same way in humans.
Growth factor predicts poor outcome in breast cancer
The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the
Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.
Variation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.